ProMIS Neurosciences Inc. (NASDAQ: PMN) announced it has enrolled 144 patients in its PRECISE-AD Phase 1b clinical trial of PMN310 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE